AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02542176 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grape Powder Placebo
Description: 60 g of grape powder placebo for 4 weeks
Study NCT03509324 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin LISPRO
Description: receive short-term insulin pump therapy by using insulin LISPRO, continue treatment for 7 more days when euglycemia achieved
Study NCT03041311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib IV
Study NCT03041311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV
Study NCT03041311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV
Study NCT03041311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide IV
Study NCT00608920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography (SPECT)
Study NCT02503046 — intervention group
Intervention type: OTHER
Intervention: Estimation of Pentraxin3
Description: 5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
Study NCT03041311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab IV
Study NCT01299727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhHNS-10 mg
Description: Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
Study NCT01299727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhHNS-45 mg
Description: Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
Study NCT01299727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhHNS-90 mg
Description: Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
Study NCT00955058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCP
Description: Daily For 3 months
Study NCT02503046 — intervention group
Intervention type: GENETIC
Intervention: Estimation of P.Gingivalis levels
Description: Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
Study NCT00955058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCP
Description: Daily For 3 months
Study NCT03049449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells
Description: Dose-escalation trial starting dose: 0.3x10\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
Study NCT03231683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
Study NCT03231683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
Study NCT03231683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
Study NCT03231683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
Study NCT02719561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue Intervention
Description: The Fatigue Intervention will include education, energy conservation and activity promotion
Study NCT00592774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007 (perampanel)
Description: 2 mg titrated up to 8 mg maximum; taken once daily.
Study NCT00592774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg titrated up to 8 mg maximum; taken once daily.
Study NCT00592774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 mg titrated up to 8 mg maximum; taken once daily.
Study NCT04363151 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Study NCT02847572 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cataract Surgery
Description: All patients wil be having intraocular lens surgery
Study NCT03896347 — intervention group
Intervention type: OTHER
Intervention: ViBone®
Description: Viable bone allograft
Study NCT03896347 — intervention group
Intervention type: OTHER
Intervention: Demineralized Bone Matrix
Description: Demineralized Bone Matrix
Study NCT03049449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 or 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
Study NCT03049449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
Study NCT01724957 — intervention group
Intervention type: PROCEDURE
Intervention: Intracoronary ECG
Description: Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
Study NCT02555163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HoLERBT
Description: Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
Study NCT02555163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cTURBT
Description: using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
Study NCT02281890 — intervention group
Intervention type: OTHER
Intervention: Proven sepsis
Description: Exposure is proven sepsis
Study NCT02069691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality-cycling training system
Study NCT01627418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Voucher
Description: Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
Study NCT01627418 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No intervention : control arm
Description: Do not receive the money or pamphlet in the initial study year
Study NCT01808560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow Pre-Treatment
Description: The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
Study NCT01808560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow Post-treatment
Description: The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
Study NCT02493647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Love, Sex, & Choices
Description: Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.
Study NCT03330327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: HM12470 is a long-acting insulin analogue
Study NCT00703313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5% levofloxacin ophthalmic solution
Description: 1 drop instilled at each visit
Study NCT00703313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% moxifloxacin hydrochloride ophthalmic solution
Description: 1 drop instilled at each visit
Study NCT00703313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% gatifloxacin ophthalmic solution
Description: 1 drop instilled at each visit
Study NCT02844127 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Implantable Cardioverter Defibrillator (ICD)
Description: Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
Study NCT01323907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven IV lipid emulsion
Description: For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
Study NCT03971188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with Internal Brace
Description: Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.
Study NCT03971188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapeziectomy with Internal Brace
Description: Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.
Study NCT04626414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric maltol capsule
Description: single dose of 30 mg capsule
Study NCT04626414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric maltol suspension
Description: single dose of 30mg (5ml) oral suspension
Study NCT00712374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfadoxine-pyrimethamine plus amodiaquine
Description: SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine
Study NCT02818699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
Study NCT02818699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EMIQ
Description: 280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
Study NCT00586365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: 500 mg Naproxen twice a day for two weeks
Study NCT00766792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nocturnal dialysis
Description: Switch to nocturnal dialysis (3 times 480 min/week)
Study NCT00766792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dialysis
Description: Standard dialysis (3 times 240-270 min/week)
Study NCT00575861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zileuton
Description: zileuton (Zyflo) 600mg qid for 2hr and for 30 days
Study NCT02303925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NESTER COILS
Study NCT04007159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum
Description: Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square \[mL/cm\^2\] of serum in an individual cell of patch)
Study NCT04007159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lotion
Description: Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of lotion in an individual cell of patch)
Study NCT04007159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream
Description: Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of cream in an individual cell of patch)
Study NCT04007159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of normal saline in an individual cell of patch)
Study NCT02388295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3241
Description: Drug: AZD3241 administered for 12 weeks orally as a tablet.
Study NCT02388295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
Study NCT01755988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational website (in addition to usual care).
Study NCT01755988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website and interactive platform with telemonitoring.
Study NCT02786069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl L-carnitine Hydrochloride
Description: 500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
Study NCT01057277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001(Afinitor)
Description: Rad001 in combination withCisplatin and Concurrent RT
Study NCT01036399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
Study NCT04024592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex System 4
Description: Reliability and validity of isokinetic strength measurement of the knee, hip and ankle in typically developing children.
Study NCT02906800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
Study NCT03382093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Feedback Intervention
Description: Personalized Feedback Intervention for smoking and anxiety.
Study NCT03382093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Information Control
Description: Smoking Information with no personalized feedback.
Study NCT03276299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: six minute walking test
Description: six minute walking test
Study NCT03350347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: Starting dose of 25 mg or 50 mg molidustat once daily (OD) will be titrated based on the subject's Hb response
Study NCT03350347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Starting dose and frequency of darbepoetin alfa are based on previous ESA. The dose will be titrated based on the subject's Hb response
Study NCT03682159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual lymphatic drainage
Description: The intervention group received the same conventional postoperative cares as the control group, but also underwent 5 sessions of manual lymphatic drainage (MLD)
Study NCT01304641 — intervention group
Intervention type: OTHER
Intervention: Atorvastatin Initiators
Description: Retrospective database analysis no intervention performed.
Study NCT01304641 — intervention group
Intervention type: OTHER
Intervention: Simvastatin Initiators
Description: Retrospective database analysis no intervention performed.
Study NCT03596944 — intervention group
Intervention type: DRUG
Intervention: Statin
Description: Prescribed with statins for primary prevention
Study NCT02286388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.
Description: Instruments and procedures:~* Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~* Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin).
Study NCT02286388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.
Description: Instruments and procedures:~* Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~* Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin).
Study NCT01644253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 mg/kg TRU-016 + Rituximab
Description: TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses
Study NCT01644253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg TRU-016 + Rituximab
Description: TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule
Study NCT01644253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-016 20 mg/kg + Obinutuzumab
Description: TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months~Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months
Study NCT01644253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-016 6-20 mg/kg + idelalisib + rituximab
Description: TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.
Study NCT01644253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-016 10-20 mg/kg + ibrutinib
Description: TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.
Study NCT02286388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.
Description: Instruments and procedures:~Idem partial excavation arm.~In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin.
Study NCT02286388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.
Description: Instruments and procedures:~Idem partial excavation arm.~In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin.